Altimmune, Inc. (ALT)
| Market Cap | 532.86M +27.4% |
| Revenue (ttm) | 36,000 +80.0% |
| Net Income | -91.08M |
| EPS | -0.91 |
| Shares Out | 194.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,512,579 |
| Open | 2.800 |
| Previous Close | 2.800 |
| Day's Range | 2.730 - 2.840 |
| 52-Week Range | 2.560 - 7.730 |
| Beta | 0.17 |
| Analysts | Buy |
| Price Target | 16.06 (+486.13%) |
| Earnings Date | May 13, 2026 |
About ALT
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Financial Performance
In 2025, Altimmune's revenue was $41,000, an increase of 105.00% compared to the previous year's $20,000. Losses were -$88.09 million, -7.33% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ALT stock is "Buy." The 12-month stock price target is $16.06, which is an increase of 486.13% from the latest price.
News
Altimmune price target lowered to $20 from $25 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Altimmune (ALT) to $20 from $25 and keeps a Buy rating on the shares. The price target cut reflects…
Altimmune price target lowered to $11 from $14 at Citizens
Citizens lowered the firm’s price target on Altimmune (ALT) to $11 from $14 and keeps an Outperform rating on the shares. Pemvidutide is a differentiated and compelling metabolic dysfunction-associate...
Altimmune Earnings Call Transcript: Q1 2026
Raised $225M in April, boosting cash to $535M and securing runway through 2029. Advancing pemvidutide with phase III MASH trial to start H2 2026, phase II AUD data due next quarter, and strong focus on tolerability and efficacy to differentiate in a competitive market.
Altimmune Earnings release: Q1 2026
Altimmune released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Altimmune Quarterly report: Q1 2026
Altimmune has published its Q1 2026 quarterly earnings report on May 13, 2026.
Altimmune reports Q1 EPS (18c), consensus (25c)
“We continue to make significant progress across multiple fronts, as we enter a new phase for Altimmune (ALT),” said Jerry Durso, president and CEO of Altimmune. “As a result of…
Altimmune Announces First Quarter 2026 Financial Results and Business Update
Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m. ET G...
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASL
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today annou...
Altimmune management to meet with Piper Sandler
Meeting to be held in New York on April 28 hosted by Piper Sandler.
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital...
Altimmune upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Corinne Johnson upgraded Altimmune (ALT) to Neutral from Sell with a price target of $2.50, up from $1. The company’s financing this week brings its pro forma…
Altimmune 64.25M share Spot Secondary priced at $3.00
Leerink and Barclays acted as joint book running managers for the offering.
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ann...
Altimmune announces common stock offering, no amount given
Altimmune (ALT) announced it has commenced an underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase an equivalent number of shares of its…
Altimmune Announces Proposed Underwritten Public Offering of Securities
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ann...
Altimmune Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and amendments to share authorization and employee stock plans. All proposals passed by majority or plurality vote, with results to be filed with the SEC.
Altimmune initiated with a Buy at Truist
Truist initiated coverage of Altimmune (ALT) with a Buy rating and $12 price target The firm believes that Altimmune’s lead asset, pemvidutide, “could be successful in treating MASH as well…
Altimmune Proxy statement: Proxy Filing
Altimmune filed a proxy statement on March 17, 2026, providing details for shareholder voting and corporate governance matters.
Altimmune price target raised to $25 from $12 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Altimmune (ALT) to $25 from $12 and keeps a Buy rating on the shares, citing the company’s narrowed focus on the planned…
Altimmune Transcript: Barclays 28th Annual Global Healthcare Conference
Phase II data for pemvidutide in MASH showed strong resolution and anti-fibrotic effects, supporting a differentiated phase III design with AI-assisted histology. Progress continues in AUD and ALD trials, with financial and leadership enhancements positioning for late-stage success.
Altimmune Transcript: Leerink Global Healthcare Conference 2026
Recent clinical data show pemvidutide offers strong efficacy, tolerability, and a unique dual mechanism for MASH, with phase III trials designed for robust endpoints and regulatory flexibility. Ongoing studies in alcohol-related indications may further expand its therapeutic reach.
Altimmune Transcript: The Citizens Life Sciences Conference 2026
Pemvidutide is advancing toward a phase III trial in MASH, supported by strong phase II data on MASH resolution, weight loss, and tolerability. Its unique one-to-one glucagon/GLP-1 ratio and commercial strategy aim to address key unmet needs, with a solid financial runway into 2028.
Altimmune Slides: Corporate presentation
Altimmune has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.
Altimmune price target lowered to $13 from $18 at B. Riley
B. Riley lowered the firm’s price target on Altimmune (ALT) to $13 from $18 and keeps a Buy rating on the shares. Altimmune’s Q4 update highlights pemvidutide as a differentiated…